CA2473885C - Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias - Google Patents

Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias Download PDF

Info

Publication number
CA2473885C
CA2473885C CA2473885A CA2473885A CA2473885C CA 2473885 C CA2473885 C CA 2473885C CA 2473885 A CA2473885 A CA 2473885A CA 2473885 A CA2473885 A CA 2473885A CA 2473885 C CA2473885 C CA 2473885C
Authority
CA
Canada
Prior art keywords
ambroxol
treatment
pain
acceptable salts
chronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2473885A
Other languages
English (en)
French (fr)
Other versions
CA2473885A1 (en
Inventor
Wolfram Gaida
Klaus Klinder
Thomas Weiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2473885A1 publication Critical patent/CA2473885A1/en
Application granted granted Critical
Publication of CA2473885C publication Critical patent/CA2473885C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2473885A 2002-01-25 2003-01-21 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias Expired - Fee Related CA2473885C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10203104A DE10203104A1 (de) 2002-01-25 2002-01-25 Ambroxol für die Behandlung chronischer Schmerzen
DE10203104.5 2002-01-25
PCT/EP2003/000531 WO2003061642A1 (de) 2002-01-25 2003-01-21 Verwendung von ambroxol zur behandlung von chronischen schmerzen, cerebralen exzitotoxizitätsbedingten störungen und kardialen arrhythmien

Publications (2)

Publication Number Publication Date
CA2473885A1 CA2473885A1 (en) 2003-07-31
CA2473885C true CA2473885C (en) 2011-03-22

Family

ID=7713171

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2473885A Expired - Fee Related CA2473885C (en) 2002-01-25 2003-01-21 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias

Country Status (11)

Country Link
EP (1) EP1471899B1 (enExample)
JP (1) JP2005526713A (enExample)
AR (1) AR038316A1 (enExample)
AT (1) ATE376416T1 (enExample)
CA (1) CA2473885C (enExample)
DE (2) DE10203104A1 (enExample)
ES (1) ES2295588T3 (enExample)
PE (1) PE20040176A1 (enExample)
TW (1) TW200307534A (enExample)
UY (1) UY27620A1 (enExample)
WO (1) WO2003061642A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050027012A1 (en) * 2003-07-16 2005-02-03 Boehringer Ingelheim International Gmbh Tablets containing ambroxol
DE10332487A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
DE10332486A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
DE102007000521A1 (de) 2007-10-18 2009-04-23 Renate Conrad Hustenpräparat
CN109982692A (zh) 2016-11-14 2019-07-05 王明武 用于治疗眼表疾病的制剂和相关方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151912A1 (en) * 1992-12-21 1994-07-07 Richard Wilfred D'souza Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
EP0896815A4 (en) * 1996-05-02 2000-02-09 Taisho Pharmaceutical Co Ltd SUSPENSION OF A LITTLE WATER-SOLUBLE ACID MEDICINE
JP2000080034A (ja) * 1998-09-02 2000-03-21 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001151677A (ja) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd 咽頭用組成物

Also Published As

Publication number Publication date
TW200307534A (en) 2003-12-16
WO2003061642A1 (de) 2003-07-31
CA2473885A1 (en) 2003-07-31
DE50308460D1 (de) 2007-12-06
DE10203104A1 (de) 2003-08-07
ES2295588T3 (es) 2008-04-16
EP1471899A1 (de) 2004-11-03
ATE376416T1 (de) 2007-11-15
AR038316A1 (es) 2005-01-12
EP1471899B1 (de) 2007-10-24
JP2005526713A (ja) 2005-09-08
PE20040176A1 (es) 2004-04-16
UY27620A1 (es) 2003-08-29

Similar Documents

Publication Publication Date Title
JP4664505B2 (ja) ビュープロピオン代謝物質ならびにその合成方法および使用
US20240366559A1 (en) Methods of treating neurological and psychiatric disorders
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
EP2167065A1 (en) Combination therapy for depression
JP5864819B2 (ja) 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物
JP2015514727A (ja) 運動障害の管理の改善に適した経口投与可能な医薬製剤
UA122780C2 (uk) Композиції, що містять 2-((1-(2-(4-фторфеніл)-2-оксоетил)піперидин-4-іл)метил)ізоіндолін-1-он, для лікування шизофренії
HK1047545A1 (en) The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction
US20060199867A1 (en) Ambroxol for the treatment of chronic pain
CA2473885C (en) Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias
CZ20023752A3 (cs) Farmaceutický prostředek
US20230277513A1 (en) Methods of treatment of tuberous sclerosis complex
JP7048629B2 (ja) 医薬組成物およびその使用
AU2008240374A1 (en) Sustained release
US20050014845A1 (en) Ambroxol for the treatment of epilepsy
WO2005067909A1 (en) Combination therapy with mecamylamine for the treatment of mood disorders
RU2410097C2 (ru) Лекарственная форма триметазидина модифицированного высвобождения и способ ее получения (варианты)
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
KR102643197B1 (ko) 화합물 iii의 새로운 의학 용도
CA2532304A1 (en) Ambroxol for treating tinnitus
WO2025124375A1 (zh) 一种布立西坦缓释药物组合物、其制备方法及应用
CN119909043A (zh) 一种用于帕金森治疗的多体系释药系统及其制备方法
KR20130076531A (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
WO2012028834A1 (en) Use of bupropion in treating sexual dysfunction

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170123